Privia Health Group (NASDAQ:PRVA) CFO Sells $680,185.00 in Stock

Privia Health Group, Inc. (NASDAQ:PRVAGet Free Report) CFO David Mountcastle sold 24,734 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $27.50, for a total value of $680,185.00. Following the completion of the sale, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This represents a 11.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Mountcastle also recently made the following trade(s):

  • On Tuesday, July 7th, David Mountcastle sold 600 shares of Privia Health Group stock. The stock was sold at an average price of $27.57, for a total transaction of $16,542.00.
  • On Friday, June 26th, David Mountcastle sold 17,196 shares of Privia Health Group stock. The stock was sold at an average price of $25.18, for a total transaction of $432,995.28.
  • On Monday, May 11th, David Mountcastle sold 3,385 shares of Privia Health Group stock. The stock was sold at an average price of $22.60, for a total transaction of $76,501.00.
  • On Monday, May 4th, David Mountcastle sold 1,206 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total transaction of $30,150.00.
  • On Friday, May 1st, David Mountcastle sold 7,179 shares of Privia Health Group stock. The shares were sold at an average price of $25.03, for a total transaction of $179,690.37.

Privia Health Group Stock Up 2.1%

Shares of NASDAQ:PRVA opened at $27.77 on Friday. The stock has a market cap of $3.50 billion, a PE ratio of 173.57, a PEG ratio of 2.15 and a beta of 0.83. The company’s fifty day moving average is $23.71 and its 200 day moving average is $23.11. Privia Health Group, Inc. has a 52 week low of $18.77 and a 52 week high of $27.81.

Institutional Investors Weigh In On Privia Health Group

A number of institutional investors have recently bought and sold shares of the business. Bayban purchased a new stake in Privia Health Group during the 4th quarter valued at approximately $26,000. Hantz Financial Services Inc. increased its holdings in shares of Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock worth $27,000 after purchasing an additional 926 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Privia Health Group by 579.8% in the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock worth $38,000 after buying an additional 1,351 shares in the last quarter. Harbor Investment Advisory LLC bought a new position in Privia Health Group during the second quarter valued at approximately $69,000. Finally, Canada Pension Plan Investment Board boosted its stake in Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after buying an additional 1,200 shares during the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, July 2nd. Barclays lowered their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 26th. Evercore set a $26.00 price target on shares of Privia Health Group in a research report on Wednesday, April 8th. Canaccord Genuity Group cut their target price on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Zacks Research downgraded shares of Privia Health Group from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.15.

Check Out Our Latest Stock Analysis on PRVA

Privia Health Group Company Profile

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Read More

Insider Buying and Selling by Quarter for Privia Health Group (NASDAQ:PRVA)

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.